The organic nitrate NDBP promotes cardiometabolic protection in type 1 diabetic mice. (May 2023)

• Record Type: Journal Article
• Authors: Fernandes-Costa, Francineide; Gomes da Silva, Rayanelle Tissiane; Flôr, Atalia Ferreira de Lima; Cláudia R. Brandão, Maria; Athayde-Filho, Petrônio F.; França-Falcão, Maria do Socorro; de Andrade Braga, Valdir; Jorge dos Santos, Gustavo; Carlstrom, Mattias; Cruz, Josiane de Campos
• Is Part Of: Journal of functional foods. Volume 104(2023)
• Publication Date: 2023-05
• Subjects: Diabetes -- Nitric oxide -- Aorta -- Blood pressure; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2023.105526
• Languages: English
• ISSNs: 1756-4646

Abstract

Graphical abstract: Vascular and metabolic effects induced by NDBP in type 1 diabetic mice. 1 - After induction of type 1 diabetes with an intraperitoneal injection of streptozotocin (50 mg/kg/5 days), blood glucose was evaluated 7 days after the last dose of STZ. 2 - Diabetes was confirmed when blood glucose was greater than 200 mg/dL. 3 – After confirmation of diabetes, the mice were treated with NDBP (40 mg/kg) by intraperitoneal injection once a day for 14 days. 4 - Diabetic mice treated with NDBP showed decreased fasting blood glucose accompanied by increased glucose tolerance, decreased water and feed intake, decreased urinary volume, decreased oxidative stress in the liver and pancreas, and improved endothelium-independent vascular function in thoracic aorta when compared to untreated diabetic animals. Highlights: Organic donor of NO, NDBP, increases glucose tolerance of diabetic mice. NDBP treatment decreases fasting glycemia in diabetic mice. NDBP treatment increases endothelium-independent vasorelaxation in aorta of diabetic mice. NDBP treatment improves oxidative stress in liver and pancreas of diabetic mice. Abstract: Studies from our laboratory have shown that the nitric oxide (NO) donor 2-nitrate-1, 3-dibutoxypropan (NDBP) lowers blood pressure in hypertension. However, the role of NDBP in other cardiometabolic diseases such as diabetes remains unknown. Our study aimed to evaluate the cardiometabolic effect of NDBP treatment in type 1 diabetes (T1DM) mice. T1DM was induced by streptozotocin (i.p. 50 mg/kg, 5 days) and confirmed by fasting glucose (≥200 mg/dL). Following induction of T1DM, mice were treated with NDBP (40 mg/kg/day i.p.) or vehicle (cremophor in saline) for 14 days. Our data revealed that NDBP treatment in T1DM mice reduced hyperglycemia, water consumption, urine volume, and oxidative stress in the liver and pancreas and increased glucose tolerance. Furthermore, NDBP treatment improved vascular function, although it was not able to attenuate hypertension. In conclusion, our study results indicate that NDBP promotes beneficial metabolic effects and improves endothelium-independent vascular function in a mouse model of T1DM.